Any current/future capex/capital investment/strategic investment?

There is a planned capital expenditure (CAPEX) project worth Rs. 90 crores. The project is funded with Rs. 60 crores from a financer. The new facility will be an additional plant within the existing Gajraula facility. Construction and commissioning of this plant are expected to take around one year. Benefits from this CAPEX are anticipated to materialize in the financial year 2026-27 or later. No immediate turnover impact is expected in the current year from this CAPEX. The CAPEX aims to support backward integration and enhance production capabilities.

Any current/future new fundraising through debt or equity?

There is a planned new project with a CAPEX of Rs. 90 crores. This CAPEX will be funded partly by a financier providing Rs. 60 crores. The project, an additional plant at the existing Gajraula facility, is expected to start anytime soon. The plant commissioning and benefits are expected only by FY 26-27. No explicit mention of any equity fundraising or further debt beyond this financing. The company currently manages debt with interest and depreciation around Rs. 100 crores, and no foreign currency loans. No announcements of new fundraising rounds through equity in the provided transcript.

Future growth expectations in sales/revenue/volumes?

The company targets a conservative annual revenue of Rs. 1,600 to Rs. 1,700 crores for FY26-27, factoring in reduced sales returns and improved profitability. Growth is expected to be driven by an increasing contribution from patented high-margin formulations, which comprised 45% of brand sales this quarter (up from 29% last year). Revenue growth may be muted in the current year due to a strategic recalibration from a push to a pull sales model, focusing on quality over quantity. Sales in Q2 and Q3 are expected to pick up, aligned with seasonal trends, especially for herbicides, insectic

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets annual revenue of Rs. 1,600 to Rs. 1,700 crores for FY26-27, factoring in a reduced sales return rate of 10-12%. EBITDA margin is expected to exceed 15% annually, improving from 12% in Q1 FY26 with anticipated higher margins in subsequent quarters (17-18% in Q2). Profit After Tax (PAT) margin improved to 5% in Q1 and is expected to grow alongside EBITDA margins, supported by fixed depreciation and interest costs (~Rs. 100 crores annually). Operational efficiencies, including reduced operating expenses by Rs. 30-40 crores annually and a focus on patented high-margin pr

Current/ Expected Orderbook/ Pending Orders?

As per the transcript, there is no explicit mention of the current or expected order book or pending orders. The company has shifted to a "deferred placement" strategy, placing orders closer to the season (e.g., orders in July or August instead of June), which affects order timing rather than order volume. This approach aims to reduce inventory and sales returns, leading to more predictable and sustainable business. The management focuses on improving margins and reducing excess inventory rather than emphasizing order backlog. Q2 and Q3 sales are expected to be stronger due to seasonality and

IN US

Sale is live|00:00:00left today

Best Agrolife LtdQ2 FY25Fertilizers & Agrochemicals

Best Agrolife Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹15.5P/E: 28.8Market Cap: ₹697 CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 4

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 4

→The company targets a conservative annual revenue of Rs. 1,600 to Rs. 1,700 crores for FY26-27, factoring in reduced sales returns and improved profitability.
→Growth is expected to be driven by an increasing contribution from patented high-margin formulations, which comprised 45% of brand sales this quarter (up from 29% last year).
→Revenue growth may be muted in the current year due to a strategic recalibration from a push to a pull sales model, focusing on quality over quantity.
→Sales in Q2 and Q3 are expected to pick up, aligned with seasonal trends, especially for herbicides, insecticides, and fungicides.
→The company anticipates better sales volumes starting FY27 onwards as patented products ramp up and new product launches gain traction.
→International business is viewed as a significant growth opportunity over 4-5 years, with efforts underway to register products in major markets like the EU.
→Distributor sales per channel partner are expected to increase over the next 2-3 years, with some distributors already achieving Rs. 1 crore in sales.

Margin guidance

Category 1

→The company targets annual revenue of Rs. 1,600 to Rs. 1,700 crores for FY26-27, factoring in a reduced sales return rate of 10-12%.
→EBITDA margin is expected to exceed 15% annually, improving from 12% in Q1 FY26 with anticipated higher margins in subsequent quarters (17-18% in Q2).
→Profit After Tax (PAT) margin improved to 5% in Q1 and is expected to grow alongside EBITDA margins, supported by fixed depreciation and interest costs (~Rs. 100 crores annually).
→Operational efficiencies, including reduced operating expenses by Rs. 30-40 crores annually and a focus on patented high-margin products, will drive profitability.
→Deferred sales placements closer to seasons and a pivot towards in-season execution will reduce sales returns and improve working capital.
→New CAPEX (Rs. 90 crores project) will come online by FY26-27 contributing to long-term growth.
→The company aims for sustained margin expansion, predictable earnings, and improved investor confidence.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→There is a planned new project with a CAPEX of Rs. 90 crores.
→This CAPEX will be funded partly by a financier providing Rs. 60 crores.
→The project, an additional plant at the existing Gajraula facility, is expected to start anytime soon.
→The plant commissioning and benefits are expected only by FY 26-27.
→No explicit mention of any equity fundraising or further debt beyond this financing.
→The company currently manages debt with interest and depreciation around Rs. 100 crores, and no foreign currency loans.
→No announcements of new fundraising rounds through equity in the provided transcript.

Order book

→As per the transcript, there is no explicit mention of the current or expected order book or pending orders.
→The company has shifted to a "deferred placement" strategy, placing orders closer to the season (e.g., orders in July or August instead of June), which affects order timing rather than order volume.
→This approach aims to reduce inventory and sales returns, leading to more predictable and sustainable business.
→The management focuses on improving margins and reducing excess inventory rather than emphasizing order backlog.
→Q2 and Q3 sales are expected to be stronger due to seasonality and placement strategy, particularly with patented products gaining traction.
→No specific numbers related to the order book or pending orders are disclosed or discussed on page 16 or surrounding content.

Capex plans

Yes

→There is a planned capital expenditure (CAPEX) project worth Rs. 90 crores.
→The project is funded with Rs. 60 crores from a financer.
→The new facility will be an additional plant within the existing Gajraula facility.
→Construction and commissioning of this plant are expected to take around one year.
→Benefits from this CAPEX are anticipated to materialize in the financial year 2026-27 or later.
→No immediate turnover impact is expected in the current year from this CAPEX.
→The CAPEX aims to support backward integration and enhance production capabilities.

How does Best Agrolife Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1Best Agrolife Ltd

Rev 4Mar 1

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like Best Agrolife Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio